Insulet Corporation (PODD)
Dispositivos médicos
Leader in tubeless insulin pumps (Omnipod) with high-teens growth, return on invested capital near 20%, and a moat built on patents and patient/payer switching costs, trading 58% below its 52-week high after a guidance cut centered on U.S. type 2 diabetes patient retention -while international guidance, nearly a third of revenue, was actually raised.
- Price
- $143.52
- Intrinsic value (5y, base)
- $275
- Total annual return (5y)
- 13.9%
- Status (nominal)
- Undervalued
- Margin of safety
- +35%
The essentials
- TTM revenue of $3,053M growing 29.4% year over year, with the Omnipod platform accounting for practically the entire business.
- Return on invested capital of ~20%, well above the 10% bar, backed by more than 1,000 active patents and regulatory barriers in every market.
- The Aug 5, 2026 release cut U.S. revenue guidance (17-19% from 20-22%) on type 2 diabetes patient attrition in the first 90 days, while raising international guidance (30-32% from 26-28%).
Intrinsic value — two valuation methods
By both methods, the value today (DCF $199 · Multiples $221) exceeds the market price ($144).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $144 trades ~35.0% below its value discounted to today (~$221); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — Infravalorado: the target price ($275) plus dividends yield above the required average return (10%) — the business compounds.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$137.
Thesis
The business
Insulet is the technology leader in tubeless insulin pumps, with a product (Omnipod 5) protected by more than 1,000 patents and regulatory barriers in every market, generating recurring revenue from device replacement every three days. Return on invested capital runs around 20%, well above the 10% bar, in a business that keeps growing strongly.
The valuation
The multiples-based valuation on adjusted earnings projected 5 years out yields a value of $275 per share in the base scenario, with an exit multiple of 11× within the 16-22x band of the medical-device archetype. Against the market price of $144, this implies an annual return of +14%.
The margin of safety
It trades at a real discount to value, though short of the required margin of safety. The current price reflects, in part, the 58% drop from the 52-week high following the Aug 5, 2026 guidance cut, which hit the U.S. segment squarely while the international segment -nearly a third of revenue- saw its guidance raised in the same release.
What to watch
The central disconfirmer of the thesis is whether type 2 diabetes patient attrition in the first 90 days is a transitory execution problem (as the company itself describes it) or a signal that the type 2 market is structurally harder to retain than the company's historical type 1 base. If retention does not improve over the coming quarters, consolidated growth could decelerate faster than modeled in the adverse scenario.
Educational / informational. Does not constitute investment advice.